Cigarette maker Philip Morris International Inc (PMI) has clinched a ￡1 billion (US$1.38 billion) takeover of inhaler maker Vectura Group PLC after winning the backing of about 75 percent of the British company’s shareholders.
Vectura shareholders had until Wednesday to decide whether to support the ￡1.65 per share bid from Philip Morris, which sought to buy the London-listed asthma drug maker as part of its plan to go “smoke-free” and switch to healthcare and wellness products.
“We have reached an important milestone in our acquisition of Vectura and are pleased to have secured over 74 percent of the company’s shares, in excess of the 50 percent required to make our offer unconditional and PMI the majority shareholder,” CEO Jacek Olczak said in a statement yesterday.
PMI had received the shares from shareholders through a public tender offer process, and the cigarette maker’s offer for Vectura can no longer be withdrawn.
PMI, which fought off private equity firm Carlyle Group for the buyout of Vectura, had switched its proposal to a takeover offer from a so-called scheme of arrangement to raise its chances.
The switch allowed PMI to require the support of holders of slightly more than 50 percent of Vectura shares for the deal to go through.
While PMI has received regulatory clearances for the deal and won the backing of Vectura’s board, health groups are questioning the idea of a tobacco company making money from treating the very illnesses that cigarettes cause.
Olczak said that PMI would provide Vectura’s scientists with the resources and expertise to reach a target of at least US$1 billion in net revenue from its Beyond Nicotine products by 2025.
The US-based company has also extended the deadline to Sept. 30 for the remaining Vectura shareholders to tender their shares.
Malaysia is scrambling to protect its assets as the descendants of the last sultan of the remote Philippine region of Sulu look to enforce a US$15 billion arbitration award in a dispute over a colonial-era land deal. In 1878, two European colonists signed a deal with the sultan for the use of his territory in present-day Malaysia — an agreement that independent Malaysia honored until 2013, paying the monarch’s descendants about US$1,000 per year. Now, 144 years later after the original deal, Malaysia is on the hook for the second-largest arbitration award on record for stopping the payments after a bloody incursion
RECOVERED CONFIDENCE: As market rationality returns, Taiwanese stocks that have lagged behind their US peers might soon catch up, Allianz researchers said Local shares last week defied heavy pressure from China’s military drills in waters around Taiwan, and investors this week are expected to pay attention to earnings results from several tech heavyweights as well as the latest economic data on exports and GDP. The TAIEX closed at 15,036.04 points on Friday, posting a weekly increase of 0.24 percent from 15,000.07 on July 29, Taiwan Stock Exchange data showed. Over the same period, the FTSE TWSE Taiwan 50 Index, which comprises Taiwan’s top 50 stocks in terms of market capitalization, closed up 0.93 percent at 11,750.15 points, while the Formosa Stock Index, which measures
Pharmaceutical start-up AcadeMab Biomedical Inc (研生生醫) said it has been developing a COVID-19 antibody drug, an endeavor not being undertaken by many other Taiwanese pharmaceutical firms. The company was spun off from Academia Sinica’s Institute of Cellular and Organismic Biology in 2020 and has only 16 employees. It has set its sights on the innovative field of the monoclonal antibody treatment of tumors. The start-up began developing antibody drugs in January, after seeing that COVID-19 vaccines could not effectively protect people from new variants of SARS-CoV-2, AcadeMab Biomedical chief strategy officer Pearl Fong (俸清珠) said in an interview with the Taipei Times
FORECAST EXCEEDED: China’s curbs on some Taiwanese goods are unlikely to affect trade given inter-reliance in the electronics industries, a finance ministry official said Exports last month spiked 14.2 percent to US$43.32 billion, the second-highest increase on record and the 25th consecutive month of gains, driven by global demand for electronics used in high-performance computing and vehicles, the Ministry of Finance said yesterday. The ministry expects the trend to sustain this month and beyond, although the pace could slow due to inventory corrections for laptops, smartphones and other consumer electronics. “The July results proved stronger than expected despite rising fears over economic uncertainty,” Department of Statistics Director-General Beatrice Tsai (蔡美娜) said, adding that a high sales season in the West and stabilized COVID-19 infections in China